NEW YORK (GenomeWeb News) – Pacific Edge today announced it has signed on payor America's Choice Provider Network, expanding access to its bladder cancer test.

ACPN's clients include contracted insurance carriers, third-party administrators, health and welfare funds, employer groups, and self-insured health plans. According to Pacific Edge, 14 million patients in ACPN's network now will have access to its Cxbladder test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.